Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients
<p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a pote...
שמור ב:
| מחבר ראשי: | |
|---|---|
| מחברים אחרים: | , , |
| יצא לאור: |
2025
|
| נושאים: | |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| _version_ | 1849927644675571712 |
|---|---|
| author | Kaixiang He (13263834) |
| author2 | Fujiang Xu (5506013) Li Xiang (586649) Yuhao Luo (2826512) |
| author2_role | author author author |
| author_facet | Kaixiang He (13263834) Fujiang Xu (5506013) Li Xiang (586649) Yuhao Luo (2826512) |
| author_role | author |
| dc.creator.none.fl_str_mv | Kaixiang He (13263834) Fujiang Xu (5506013) Li Xiang (586649) Yuhao Luo (2826512) |
| dc.date.none.fl_str_mv | 2025-11-24T13:40:08Z |
| dc.identifier.none.fl_str_mv | 10.6084/m9.figshare.30695059.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Albumin_globulin_ratio_is_a_predictive_biomarker_of_antitumour_effect_of_immune_checkpoint_inhibitors_in_cancer_patients/30695059 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Cell Biology Pharmacology Immunology Cancer Science Policy Mathematical Sciences not elsewhere classified Immune checkpoint inhibitors renal cell carcinoma cancer prognosis therapeutic response |
| dc.title.none.fl_str_mv | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort.</p> <p>A systematic literature search was conducted using PubMed, EMBASE, and the Cochrane Library to identify studies published prior to June 6, 2025. The primary endpoints were overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). In addition, a retrospective analysis was performed on a cohort of 74 patients with renal cell carcinoma (RCC) treated with ICIs at our institution to assess the prognostic value of baseline AGR in relation to OS and PFS.</p> <p>Seven studies encompassing 1,460 patients were included in the meta-analysis. Higher pretreatment AGR was significantly associated with improved OS (HR = 0.44; 95% CI: 0.30–0.66; <i>p</i> < 0.001), extended PFS (HR = 0.61; 95% CI: 0.53–0.71; <i>p</i> < 0.001), and superior DCR (OR = 4.48; 95% CI: 2.58–7.77; <i>p</i> < 0.001). Sensitivity analyses confirmed the robustness of these associations. In our institutional RCC cohort, elevated AGR was independently linked to prolonged OS (<i>p</i> = 0.017) and PFS (<i>p</i> = 0.030), consistent with findings from the pooled data.</p> <p>AGR is a simple, inexpensive, and non-invasive biomarker with significant prognostic value in patients undergoing ICI therapy. These findings support its potential role in guiding clinical decision-making and optimizing patient selection for immunotherapy.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_12e6777361def06f677ec54380df70b3 |
| identifier_str_mv | 10.6084/m9.figshare.30695059.v1 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30695059 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patientsKaixiang He (13263834)Fujiang Xu (5506013)Li Xiang (586649)Yuhao Luo (2826512)MedicineCell BiologyPharmacologyImmunologyCancerScience PolicyMathematical Sciences not elsewhere classifiedImmune checkpoint inhibitorsrenal cell carcinomacancerprognosistherapeutic response<p>Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort.</p> <p>A systematic literature search was conducted using PubMed, EMBASE, and the Cochrane Library to identify studies published prior to June 6, 2025. The primary endpoints were overall survival (OS), progression-free survival (PFS), and disease control rate (DCR). In addition, a retrospective analysis was performed on a cohort of 74 patients with renal cell carcinoma (RCC) treated with ICIs at our institution to assess the prognostic value of baseline AGR in relation to OS and PFS.</p> <p>Seven studies encompassing 1,460 patients were included in the meta-analysis. Higher pretreatment AGR was significantly associated with improved OS (HR = 0.44; 95% CI: 0.30–0.66; <i>p</i> < 0.001), extended PFS (HR = 0.61; 95% CI: 0.53–0.71; <i>p</i> < 0.001), and superior DCR (OR = 4.48; 95% CI: 2.58–7.77; <i>p</i> < 0.001). Sensitivity analyses confirmed the robustness of these associations. In our institutional RCC cohort, elevated AGR was independently linked to prolonged OS (<i>p</i> = 0.017) and PFS (<i>p</i> = 0.030), consistent with findings from the pooled data.</p> <p>AGR is a simple, inexpensive, and non-invasive biomarker with significant prognostic value in patients undergoing ICI therapy. These findings support its potential role in guiding clinical decision-making and optimizing patient selection for immunotherapy.</p>2025-11-24T13:40:08ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.6084/m9.figshare.30695059.v1https://figshare.com/articles/dataset/Albumin_globulin_ratio_is_a_predictive_biomarker_of_antitumour_effect_of_immune_checkpoint_inhibitors_in_cancer_patients/30695059CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/306950592025-11-24T13:40:08Z |
| spellingShingle | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients Kaixiang He (13263834) Medicine Cell Biology Pharmacology Immunology Cancer Science Policy Mathematical Sciences not elsewhere classified Immune checkpoint inhibitors renal cell carcinoma cancer prognosis therapeutic response |
| status_str | publishedVersion |
| title | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| title_full | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| title_fullStr | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| title_full_unstemmed | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| title_short | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| title_sort | Albumin–globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients |
| topic | Medicine Cell Biology Pharmacology Immunology Cancer Science Policy Mathematical Sciences not elsewhere classified Immune checkpoint inhibitors renal cell carcinoma cancer prognosis therapeutic response |